Bridging Immunity to Cancer

Rationale
Cancer disease is a leading cause of mortality worldwide with approximately 8 million deaths annually all around the globe. Despite the clinical success of immunotherapy, numerous cancer patients do not respond to treatment or develop severe toxicities that lead to treatment discontinuation. Advancements in oncology rely on multidisciplinary basic and preclinical research and on advanced disease models and systems investigating the complexity of tumor-immune cell interactions.

This Workshop will provide an update on the most recent research outcomes bridging host immunity to cancer disease. In particular, it will provide an overview of key findings concerning tumor heterogeneity and tumor microenvironment, of the new advances in anticancer therapy and of innovative in vitro and in silico ad hoc models for immuno-oncology basic and preclinical research.

Aims and objectives
Tumor immunology is a relevant area of study for all the scientists and physicians working in the oncology field. The main scope of this Workshop is to provide and update on the most recent findings regarding tumor-immune cell interactions, innovative therapeutic approaches and advanced models employed to investigate the complex interactions between cancer cells and immune system.

Training method
Online presentations with scientific session discussions.